• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hyperglycemia - Pipeline Review, H2 2012 Product Image

Hyperglycemia - Pipeline Review, H2 2012

  • Published: October 2012
  • 41 pages
  • Global Markets Direct

Hyperglycemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hyperglycemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hyperglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperglycemia. Hyperglycemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hyperglycemia.
- A review of the Hyperglycemia products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Hyperglycemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hyperglycemia 7
Hyperglycemia Therapeutics under Development by Companies 9
Hyperglycemia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Hyperglycemia Therapeutics – Products under Development by Companies 15
Hyperglycemia Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Hyperglycemia Therapeutics Development 17
IPCA Laboratories Limited 17
Relypsa, Inc. 18
Hyperglycemia – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
exenatide - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Insulin + Symlin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Insulin + Byetta - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Glucagon Like Peptide-1 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
insulin human - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
pasireotide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RLY-106 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Urocortin 3 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CJ-30001 + CJ-30002 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Hydroxychloroquine + Atorvastatin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Hyperglycemia Therapeutics – Drug Profile Updates 36
Hyperglycemia Therapeutics - Dormant Products 37
Hyperglycemia – Product Development Milestones 38
Featured News & Press Releases 38
Dec 06, 2011: Study Shows Combination Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia In Type 1 And Type 2 Diabetes Patients 38
Nov 15, 2011: PhaseBio Announces Positive Results From Phase I/IIa Trial Of Glymera For Treatment Of Hyperglycemia In Patients With Type 2 Diabetes 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Hyperglycemia, H2 2012 7
Products under Development for Hyperglycemia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
IPCA Laboratories Limited, H2 2012 17
Relypsa, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Hyperglycemia Therapeutics – Drug Profile Updates 36
Hyperglycemia Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Hyperglycemia, H2 2012 7
Products under Development for Hyperglycemia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos